(BUSINESS WIRE Release, December 13, 2017)

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE:PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) has approved IXIFI™ (PF-06438179, infliximab-qbtx), a chimeric human-murine monoclonal antibody (mAb) against tumor necrosis factor, as a biosimilar to Remicade®(infliximab)* for all eligible indications of the reference product.

Read more here:



New & Noteworthy